All In Biotech

Drug Trial Radar · NCT05710692

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease (RISE)

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Aug 1, 2023

Primary completion

Oct 2027

Study completion Aug 2029

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 13 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.

Conditions

  • Fabry Disease

Interventions

  • PRX-102 1 mg/kg every 2 weeksDrug

    PRX-102 1 mg/kg every 2 weeks

  • PRX-102 2 mg/kg every 4 weeksDrug

    PRX-102 2 mg/kg every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  2. Incidence of Infusion Related Reactions (IRRs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  3. Incidence of Injection site reactions (ISRs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  4. Change of laboratory tests' resultsTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  5. Change in in body weight in kilogramsTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  6. Change in height in centimetersTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  7. Change in Tanner stageTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  8. Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate, PR Interval, QRS Duration, QT Interval, QTc Interval, and ST SegmentTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  9. Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  10. ADA status change from baselineTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  11. Incidence of premedication use at each visit and change of infusion premedications from baselineTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
  12. Change from baseline of Maximum plasma concentration (Cmax), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  13. Change from baseline of Time to maximum plasma concentration (tmax), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  14. Change from baseline of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  15. Change from baseline of Area under the curve from time 0 to 2 weeks (AUC0-2wk), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  16. Change from baseline of Area under the curve from time 0 to infinity (AUC0-∞), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  17. Change from baseline of Terminal half-life (t1/2), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  18. Change from baseline of Area under the curve over a dosing interval (AUCτ), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  19. Change from baseline of Observed drug concentration at the end of the dosing interval (Cτ), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  20. Change from baseline of Clearance (Cl), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
  21. Change from baseline of Volume of distribution (Vz), pharmacokinetic parametersTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Asahikawa Medical University Hospital

    Asahikawa, Japan · Recruiting

  • Niigata University Medical & Dental Hospital

    Niigata, Japan · Recruiting

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan · Not yet recruiting

  • Fukuoka University Chikushi Hospital

    Chikushino-shi, Fukuoka, Japan · Withdrawn

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Recruiting

  • University of the Ryukyu Hospital

    Nishihara, Okinawa, Japan · Recruiting

  • Osaka University Hospital

    Suita, Osaka, Japan · Recruiting

  • Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Tokyo Jikei University Hospital

    Minato-ku, Tokyo, Japan · Recruiting

  • Keio University Hospital

    Shinjuku-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.